Table 2.
Estimated rates of change in weight a before and after switch from TDF to TAF
|
On TDF 60 to 0 months |
On TAF 0 to 9 months |
On TAF 9+ months |
|
|---|---|---|---|
| kg/year (95% CI) | kg/year (95% CI) | kg/year (95% CI) | |
| Maintained all other ARVs | |||
| Overall | 0.48 (0.37, 0.59) | 2.43 (2.15, 2.71) | 0.24 (0.07, 0.41) |
| NNRTI | 0.66 (0.51, 0.81) | 2.25 (1.78, 2.71) | 0.20 (−0.14, 0.54) |
| Boosted PI | 0.31 (−0.02, 0.64) | 1.98 (1.13, 2.83) | −0.11 (−0.57, 0.35) |
| InSTI | 0.42 (0.26, 0.59) | 2.64 (2.26, 3.01) | 0.29 (0.08, 0.51) |
| Maintained an InSTI | |||
| Elvitegravir/cobicistat | 0.71 (0.53, 0.90) | 2.51 (2.05, 2.96) | 0.36 (0.12, 0.61) |
| Dolutegravir | 0.73 (0.34, 1.11) | 2.38 (1.64, 3.13) | −0.18 (−0.64, 0.28) |
| Raltegravir | −0.44 (−0.79, −0.08) | 1.80 (0.57, 3.03) | 0.63 (−0.20, 1.46) |
| Switched from non‐InSTI to InSTI | |||
| Elvitegravir/cobicistat | 0.24 (0.04, 0.43) | 2.55 (1.86, 3.24) | 0.26 (−0.10, 0.61) |
| Dolutegravir | 0.22 (−0.08, 0.52) | 3.09 (1.26, 4.93) | −0.23 (−1.62, 1.16) |
| Bictegravir b | 0.01 (−0.38, 0.39) | 4.47 (0.81, 8.13) | −9.97 (−23.79, 3.85) |
ARV, antiretroviral; BMI, body mass index; CI, confidence interval; PI, boosted protease inhibitor; InSTI, integrase strand transfer inhibitor; NNRTI, non‐nucleoside reverse transcriptase inhibitor; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate.
a
Estimated with linear mixed model with linear splines on time, adjusted for age, race, sex (interaction term between age‐sex and race‐sex), BMI, CD4 cell count, endocrine disorders and medications associated with weight gain/loss
b
limited follow‐up beyond nine months.